title: Generalized hypopigmentation due to imatinib: a fairness boon?
authors.forename: Atul
authors.initials: A
authors.lastname: Sharma
authors.forename: Amish
authors.initials: A
authors.lastname: Vora
authors.forename: Manisha
authors.initials: M
authors.lastname: Bhutani
mesh_terms: D001549:Benzamides; D001707:Biopsy, Needle; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D017496:Hypopigmentation / Q000139:chemically induced* / Q000453:epidemiology* / Q000473:pathology; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D015994:Incidence; D007194:India / Q000453:epidemiology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate